DCPH News and Press, Deciphera Pharmaceuticals Inc. From 03/26/19

Deciphera Pharmaceuticals ( DCPH ) is a small company with a pipeline of small molecules targeting various causes of cancer. Lead candidate Ripretinib is an orally administered kinase switch control inhibitor being developed for the treatment of "gastrointestinal stromal tumors (GIST), advan...

Deciphera Pharmaceuticals (NASDAQ: DCPH ): Q4 GAAP EPS of -$0.86. More news on: Deciphera Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

- Enrollment Completed in INVICTUS Pivotal Phase 3 Clinical Study in Fourth-line and Fourth-line Plus GIST; Top-line Data Expected in Mid-2019 - - INTRIGUE Pivotal Phase 3 Clinical Study Initiated in Second-line Patients with GIST - - Ended 2018 with Cash and Cash Equivalents of $...

This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 02/14/2019. Please visit our Tracking Ole Andreas Halvorsen&#...

Current Deciphera Director and Experienced Commercial Oncology Executive, Steve Hoerter, Appointed as New President & Chief Executive Officer — Outgoing CEO Michael D. Taylor, Ph.D. to Continue to Serve as a Member of Board of Directors — Deciphera Pharmaceutica...

The following slide deck was published by Deciphera Pharmaceuticals, Inc. in conjunction with this Read more ...

Biotech Pulse Biotech tumbled off a steep ski slope in the last quarter, and at the December low, the Nasdaq Biotechnology Index ( IBB ) had declined -28%, while the S&P Biotech Select Index ( XBI ) a whopping -36%. But it seems biotechs were able to regain their composure at the lows an...

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that Michael Taylor, Ph.D., President and Chief Executive Officer, will present at the 1 st Annual Guggenheim Healthcare T...